JP2014531441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531441A5 JP2014531441A5 JP2014530260A JP2014530260A JP2014531441A5 JP 2014531441 A5 JP2014531441 A5 JP 2014531441A5 JP 2014530260 A JP2014530260 A JP 2014530260A JP 2014530260 A JP2014530260 A JP 2014530260A JP 2014531441 A5 JP2014531441 A5 JP 2014531441A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- hexyl
- amino
- phenylcarbamoyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzyloxy, phenyl Chemical group 0.000 claims description 34
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 10
- FZXCPFJMYOQZCA-BYPYZUCNSA-N (2s)-6-oxopiperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCC(=O)N1 FZXCPFJMYOQZCA-BYPYZUCNSA-N 0.000 claims description 3
- AMOCDUAYMXFIHU-DLBZAZTESA-N (2R)-N-[(2S)-1-anilino-7-ethoxycarbothioyloxy-1-oxoheptan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound O=C1CC[C@@H](N1)C(=O)N[C@@H](CCCCCOC(OCC)=S)C(NC1=CC=CC=C1)=O AMOCDUAYMXFIHU-DLBZAZTESA-N 0.000 claims description 2
- NEGLYSNZRMUEHF-ZEQRLZLVSA-N (2s)-6-oxo-n-[(2s)-1-oxo-1-[(3-phenylmethoxyphenyl)methylamino]-7-sulfanylheptan-2-yl]piperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NCC=1C=C(OCC=2C=CC=CC=2)C=CC=1)C(=O)[C@@H]1CCCC(=O)N1 NEGLYSNZRMUEHF-ZEQRLZLVSA-N 0.000 claims description 2
- QVHKENDYYOPWET-IRXDYDNUSA-N (2s)-6-oxo-n-[(2s)-1-oxo-7-sulfanyl-1-[[4-(trifluoromethyl)phenyl]methylamino]heptan-2-yl]piperidine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)[C@H](CCCCCS)NC(=O)[C@H]1NC(=O)CCC1 QVHKENDYYOPWET-IRXDYDNUSA-N 0.000 claims description 2
- JTIATMCBWUQBGH-IRXDYDNUSA-N (2s)-n-[(2s)-1-(3-methylanilino)-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)[C@H](CCCCCS)NC(=O)[C@H]2NC(=O)CCC2)=C1 JTIATMCBWUQBGH-IRXDYDNUSA-N 0.000 claims description 2
- PVOSRCQGYUSIRG-IRXDYDNUSA-N (2s)-n-[(2s)-1-(4-methylanilino)-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)[C@H](CCCCCS)NC(=O)[C@H]1NC(=O)CCC1 PVOSRCQGYUSIRG-IRXDYDNUSA-N 0.000 claims description 2
- QNJCPEYHBKCISJ-OALUTQOASA-N (2s)-n-[(2s)-1-[2-(3-methylphenyl)ethylamino]-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound CC1=CC=CC(CCNC(=O)[C@H](CCCCCS)NC(=O)[C@H]2NC(=O)CCC2)=C1 QNJCPEYHBKCISJ-OALUTQOASA-N 0.000 claims description 2
- PLWFKMKFFURSPO-IRXDYDNUSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-1-methyl-6-oxopiperidine-2-carboxamide Chemical compound C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCS)C(=O)NC1=CC=CC=C1 PLWFKMKFFURSPO-IRXDYDNUSA-N 0.000 claims description 2
- NYJOCLMLIASQTH-HOTGVXAUSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 NYJOCLMLIASQTH-HOTGVXAUSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-PCCBWWKXSA-N (3r,4r)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@H]2[C@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-PCCBWWKXSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-QHAWAJNXSA-N (3r,4s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@@H]2[C@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-QHAWAJNXSA-N 0.000 claims description 2
- ILCBWDQDWOLKIQ-HOTGVXAUSA-N (3s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxopiperidine-3-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCNC1=O ILCBWDQDWOLKIQ-HOTGVXAUSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-HKBOAZHASA-N (3s,4s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@@H]2[C@@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-HKBOAZHASA-N 0.000 claims description 2
- FFAADXOKPZHULO-UHFFFAOYSA-N 2-methylpropanethioic s-acid Chemical compound CC(C)C(S)=O FFAADXOKPZHULO-UHFFFAOYSA-N 0.000 claims description 2
- ILCBWDQDWOLKIQ-CVEARBPZSA-N N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCNC1=O Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCNC1=O ILCBWDQDWOLKIQ-CVEARBPZSA-N 0.000 claims description 2
- DPCLRUJQAZJUFQ-RBUKOAKNSA-N s-[(6s)-7-(3-methylanilino)-6-[[(2r)-1-methyl-5-oxopyrrolidine-2-carbonyl]amino]-7-oxoheptyl] ethanethioate Chemical compound C1CC(=O)N(C)[C@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC(C)=C1 DPCLRUJQAZJUFQ-RBUKOAKNSA-N 0.000 claims description 2
- FZVCUTATXGHVOB-ZWKOTPCHSA-N s-[(6s)-7-(3-methylanilino)-7-oxo-6-[[(2r)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=C(C)C=CC=1)C(=O)[C@H]1CCC(=O)N1 FZVCUTATXGHVOB-ZWKOTPCHSA-N 0.000 claims description 2
- QGYPCQAYENIOOF-DLBZAZTESA-N s-[(6s)-7-anilino-7-oxo-6-[[(2r)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCC(=O)N1 QGYPCQAYENIOOF-DLBZAZTESA-N 0.000 claims description 2
- QGYPCQAYENIOOF-IRXDYDNUSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCC(=O)N1 QGYPCQAYENIOOF-IRXDYDNUSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- YYSCXBPFYMVUDP-LSDHHAIUSA-N (2R)-N-[(2S)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCC(=O)N1 YYSCXBPFYMVUDP-LSDHHAIUSA-N 0.000 claims 1
- NYJOCLMLIASQTH-CVEARBPZSA-N (2R)-N-[(2S)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCC(=O)N1 NYJOCLMLIASQTH-CVEARBPZSA-N 0.000 claims 1
- LZODJSNRNSCPJV-KBPBESRZSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-4-oxoazetidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CC(=O)N1 LZODJSNRNSCPJV-KBPBESRZSA-N 0.000 claims 1
- UOQRZCNCICUPJO-IUCAKERBSA-N (3s,4r)-2-oxo-4-phenylpyrrolidine-3-carboxylic acid Chemical compound C1NC(=O)[C@@H](C(=O)O)[C@@H]1C1=CC=CC=C1 UOQRZCNCICUPJO-IUCAKERBSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- BIBVHLRGWUFEHW-OALUTQOASA-N C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 Chemical compound C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 BIBVHLRGWUFEHW-OALUTQOASA-N 0.000 claims 1
- JMVYSWLYZWSUMX-WMZOPIPTSA-N CC(=O)SCCCCC[C@@H](C(=O)NC1CCCC1)NC(=O)[C@@H]2C(=O)CCCN2 Chemical compound CC(=O)SCCCCC[C@@H](C(=O)NC1CCCC1)NC(=O)[C@@H]2C(=O)CCCN2 JMVYSWLYZWSUMX-WMZOPIPTSA-N 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- STZNXPSZBFZZRC-LBPRGKRZSA-N SCCCCC[C@H](N)C(=O)NC1=CC=CC=C1 Chemical compound SCCCCC[C@H](N)C(=O)NC1=CC=CC=C1 STZNXPSZBFZZRC-LBPRGKRZSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- MYXNWWDJRWCURH-UHFFFAOYSA-N ethoxymethanethioic s-acid Chemical compound CCOC(S)=O MYXNWWDJRWCURH-UHFFFAOYSA-N 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- CTDAROLPRDFAMC-OALUTQOASA-N s-[(6s)-7-(3-methylanilino)-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=C(C)C=CC=1)C(=O)[C@@H]1CCCC(=O)N1 CTDAROLPRDFAMC-OALUTQOASA-N 0.000 claims 1
- QYGBXTVUZBVNKJ-OALUTQOASA-N s-[(6s)-7-(4-methylanilino)-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC(C)=CC=1)C(=O)[C@@H]1CCCC(=O)N1 QYGBXTVUZBVNKJ-OALUTQOASA-N 0.000 claims 1
- FNRKKVARQRBUKS-ROUUACIJSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 FNRKKVARQRBUKS-ROUUACIJSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- PUENFUNUWKSIGX-ROUUACIJSA-N (2S)-N-[(2S)-1-anilino-7-ethoxycarbothioyloxy-1-oxoheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCOC(=S)OCC)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 PUENFUNUWKSIGX-ROUUACIJSA-N 0.000 description 1
- FZXCPFJMYOQZCA-SCSAIBSYSA-N (2r)-6-oxopiperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCC(=O)N1 FZXCPFJMYOQZCA-SCSAIBSYSA-N 0.000 description 1
- YSPMLLKKKHCTBN-REOHCLBHSA-N (2s)-4-oxoazetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=O)N1 YSPMLLKKKHCTBN-REOHCLBHSA-N 0.000 description 1
- UHKDIMIVZUCWEH-ACRUOGEOSA-N (3s,4r)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@H]2[C@@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-ACRUOGEOSA-N 0.000 description 1
- QOXLRWMTGBTFSF-GJZGRUSLSA-N N([C@@H](CCCCCS)C(=O)NC1CCCC1)C(=O)[C@@H]1CCCC(=O)N1 Chemical compound N([C@@H](CCCCCS)C(=O)NC1CCCC1)C(=O)[C@@H]1CCCC(=O)N1 QOXLRWMTGBTFSF-GJZGRUSLSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DMUPSHHTOQXMGA-ZWKOTPCHSA-N s-[(6s)-7-anilino-6-[[(2r)-1-methyl-5-oxopyrrolidine-2-carbonyl]amino]-7-oxoheptyl] ethanethioate Chemical compound C1CC(=O)N(C)[C@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 DMUPSHHTOQXMGA-ZWKOTPCHSA-N 0.000 description 1
- FNRKKVARQRBUKS-MSOLQXFVSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2r)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCC(=O)N1 FNRKKVARQRBUKS-MSOLQXFVSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181832.4 | 2011-09-19 | ||
| EP11181832 | 2011-09-19 | ||
| PCT/EP2012/068230 WO2013041480A1 (en) | 2011-09-19 | 2012-09-17 | New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531441A JP2014531441A (ja) | 2014-11-27 |
| JP2014531441A5 true JP2014531441A5 (enExample) | 2016-08-18 |
| JP6053795B2 JP6053795B2 (ja) | 2016-12-27 |
Family
ID=46888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530260A Active JP6053795B2 (ja) | 2011-09-19 | 2012-09-17 | 強力なｈｄａｃ阻害剤としてのラクタムを有する新しいチオ誘導体、及び治療剤としてのその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8927533B2 (enExample) |
| EP (1) | EP2758371B1 (enExample) |
| JP (1) | JP6053795B2 (enExample) |
| KR (1) | KR101929774B1 (enExample) |
| CN (1) | CN103732577B (enExample) |
| AU (1) | AU2012311640B2 (enExample) |
| BR (1) | BR112014006600B1 (enExample) |
| CA (1) | CA2843211C (enExample) |
| DK (1) | DK2758371T3 (enExample) |
| EA (1) | EA023171B1 (enExample) |
| ES (1) | ES2579321T3 (enExample) |
| HU (1) | HUE029687T2 (enExample) |
| IL (1) | IL230717A (enExample) |
| MX (1) | MX369508B (enExample) |
| NZ (1) | NZ620336A (enExample) |
| PH (1) | PH12014500249A1 (enExample) |
| PL (1) | PL2758371T3 (enExample) |
| PT (1) | PT2758371T (enExample) |
| UA (1) | UA111231C2 (enExample) |
| WO (1) | WO2013041480A1 (enExample) |
| ZA (1) | ZA201402790B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3076973B1 (en) * | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| WO2016201374A1 (en) * | 2015-06-11 | 2016-12-15 | University Of Florida Research Foundation, Incorporated | Sulfanide adenosine derivatives and uses thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| IT1244507B (it) * | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| BR0014254A (pt) | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| ITRM20010464A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2005051901A1 (en) * | 2003-11-28 | 2005-06-09 | The University Of Queensland | Anti-cancer agents |
| SG148218A1 (en) * | 2003-12-19 | 2008-12-31 | Jerini Ag | Compounds for the inhibition of undesired cell proliferation and use thereof |
| JP2007238452A (ja) | 2006-03-03 | 2007-09-20 | Nippon Kayaku Co Ltd | ヒストン脱アセチル化酵素を阻害する新規化合物 |
| EP2100879A1 (en) * | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
-
2012
- 2012-09-17 EP EP12761967.4A patent/EP2758371B1/en active Active
- 2012-09-17 NZ NZ620336A patent/NZ620336A/en not_active IP Right Cessation
- 2012-09-17 PT PT127619674T patent/PT2758371T/pt unknown
- 2012-09-17 WO PCT/EP2012/068230 patent/WO2013041480A1/en not_active Ceased
- 2012-09-17 CN CN201280039630.9A patent/CN103732577B/zh active Active
- 2012-09-17 PH PH1/2014/500249A patent/PH12014500249A1/en unknown
- 2012-09-17 PL PL12761967T patent/PL2758371T3/pl unknown
- 2012-09-17 HU HUE12761967A patent/HUE029687T2/en unknown
- 2012-09-17 KR KR1020147003177A patent/KR101929774B1/ko active Active
- 2012-09-17 BR BR112014006600-0A patent/BR112014006600B1/pt not_active IP Right Cessation
- 2012-09-17 UA UAA201404167A patent/UA111231C2/uk unknown
- 2012-09-17 DK DK12761967.4T patent/DK2758371T3/en active
- 2012-09-17 AU AU2012311640A patent/AU2012311640B2/en not_active Ceased
- 2012-09-17 ES ES12761967.4T patent/ES2579321T3/es active Active
- 2012-09-17 CA CA2843211A patent/CA2843211C/en active Active
- 2012-09-17 JP JP2014530260A patent/JP6053795B2/ja active Active
- 2012-09-17 MX MX2014003334A patent/MX369508B/es active IP Right Grant
- 2012-09-17 US US14/236,359 patent/US8927533B2/en active Active
- 2012-09-17 EA EA201400365A patent/EA023171B1/ru unknown
-
2014
- 2014-01-29 IL IL230717A patent/IL230717A/en active IP Right Grant
- 2014-04-16 ZA ZA2014/02790A patent/ZA201402790B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500681C2 (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
| JP2017533968A5 (enExample) | ||
| MY165906A (en) | Phenothiazine diaminium salts and their use | |
| JP2015505296A5 (enExample) | ||
| JP2016526558A5 (enExample) | ||
| JP2015516420A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2013510885A5 (enExample) | ||
| JP2014521625A5 (enExample) | ||
| JP2018511590A5 (enExample) | ||
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2011132222A5 (enExample) | ||
| JP2013523802A5 (enExample) | ||
| HRP20170736T1 (hr) | Indoli | |
| JP2015514063A5 (enExample) | ||
| UA114405C2 (uk) | Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу | |
| JP2005539045A5 (enExample) | ||
| KR101929774B1 (ko) | 락탐을 강력한 hdac 억제제로서 보유하는 신규 티오 유도체 및 약제로서 그의 용도 | |
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
| JP2018530582A5 (enExample) | ||
| JP2016522195A5 (enExample) | ||
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2016537432A5 (enExample) |